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Abstract
Background: Paroxysms are recurrent febrile episodes, characteristic of Plasmodium vivax infections, which
coincide with the rupture of schizont-infected erythrocytes in the patients' circulation. The present study
describes the formation of prominent aggregates of leukocytes in vitro in the presence of parasite and host factors
released during paroxysms.
Methods: Whole blood cells from uninfected malaria-naïve donors were incubated with plasma taken during a
paroxysm or normal human plasma as a control and cell smears were observed under the microscope for the
presence of leukocyte aggregates. Plasma factors involved in mediating the leukocyte aggregation were identified
using immune depletion and reconstitution experiments. Furthermore, biochemical characterization was carried
out to determine the chemical nature of the active moieties in plasma present during paroxysms.
Results: Leukocyte aggregates were seen exclusively when cells were incubated in plasma collected during a
paroxysm. Immune depletion and reconstitution experiments revealed that the host cytokines TNF-alpha, GM-
CSF, IL-6 and IL-10 and two lipid fractions of paroxysm plasma comprise the necessary and sufficient mediators
of this phenomenon. The two lipid components of the paroxysm plasmas speculated to be of putative parasite
origin, were a phospholipid-containing fraction and another containing cholesterol and triglycerides. The
phospholipid fraction was dependent upon the presence of cytokines for its activity unlike the cholesterol/
triglyceride-containing fraction which in the absence of added cytokines was much more active than the
phospholipids fraction. The biological activity of the paroxysm plasmas from non-immune patients who presented
with acute P. vivax infections was neutralized by immune sera raised against schizont extracts of either P. vivax or
Plasmodium falciparum. However, immune sera against P. vivax were more effective than that against P. falciparum
indicating that the parasite activity involved may be antigenically at least partially parasite species-specific.
Conclusion: Leukocyte aggregation was identified as associated with paroxysms in P. vivax infections. This
phenomenon is mediated by plasma factors including host-derived cytokines and lipids of putative parasite origin.
The characteristics of the phospholipid fraction in paroxysm plasma are congruent with those of the parasite-
derived, TNF-inducing GPI moieties described by others. The more active cholesterol/triglyceride(s), however,
represent a novel malarial toxin, which is a new class of biologically active lipid associated with the paroxysm of
P. vivax malaria.
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Background
The most characteristic presentations of acute Plasmodium
vivax infections are the periodic episodes of fever with
chills and rigors, which follow the rupture of schizont-
infected erythrocytes in the patients' circulation. Previous
investigations have been made on events associated with
paroxysms in P. vivax infections including the inactivation
of sexual stages of the parasites (gametocytes) in the pres-
ence of plasma taken at the time of a paroxysm [1,2].
These studies have demonstrated the roles in this process
of the human cytokines TNF-α, GM-CSF and IL-2 together
with parasite products. Previous studies also demon-
strated the prominent rise and fall of TNFα – levels which
corresponds very closely to the rise and fall of fever during
the paroxysms [3] and of the transient appearance of ele-
vated numbers of gamma/delta T cells in the peripheral
circulation at the time of these events [4].
In the present study, the aggregation of peripheral blood
white cells was investigated in the presence of plasmas
taken at the time of a P. vivax paroxysm. These cell aggre-
gations were formed only in the presence of paroxysm
plasma and not in the presence of plasma from before or
after a paroxysm, or from a healthy donor. Further, this
paroxysm plasma-mediated cell aggregation phenome-
non was exploited as an assay to identify and characterize
biologically active mediators of host and parasite origin
during the paroxysms of P. vivax malaria. This assay ena-
bled preliminary chemical and physical-chemical charac-
terization of parasite-derived products present and active
during a P. vivax paroxysm.
Methods
Patients
Two study groups were included. They were patients with
P. vivax infections from two localities in Sri Lanka. Those
from the first were adult residents of malaria-non-
endemic regions attending the National Hospital of Sri
Lanka, in Colombo. These patients were residents of
Colombo and its suburbs where there is no local transmis-
sion of malaria; they had acquired their infections follow-
ing travel to a malaria-endemic area of Sri Lanka. These
patients (except six patients who had one past infection)
had no previous recorded malarial infections and were
immunologically naïve (non-immune) with respect to
malaria.
The second group of patients comprised adults in a P.
vivax-endemic region of Sri Lanka at Kataragama [5]. The
patients were similarly diagnosed as having P. vivax infec-
tions by blood smear examination. All these individuals
had experienced several previous P. vivax infections (8–28
infections; median 18), as revealed during verbal inter-
view and also based on the case records. The clinical
symptoms of paroxysms were invariably milder in these
patients from Kataragama (most did not experience rig-
ors) than in non-immune patients from Colombo; these
patients were considered as clinically semi-immune with
respect to malaria [6].
Control groups
Two age and sex matched control groups were included.
One group consisted of healthy volunteers residing in
areas with no local malaria transmission and with no past
history of malaria infections. The second control group
included healthy individuals resident in Kataragama (a
malaria-endemic area). All these individuals were blood
film-negative for malaria parasites.
Cell samples
Five ml of blood samples were collected from apparently
healthy individuals residing in Colombo who were blood
film-negative for malarial parasites and who did not give
a past history of malaria. Blood was collected (and
diluted) into a solution containing Tris-1.2 mg/ml (Bio-
rad), NaCl – 8.2 mg/ml (Sigma) and Glucose – 1.8 mg/ml
(Sigma) at pH 7.4 at 10% concentration [2]. Whole blood
cells were separated by centrifugation at a speed of 800 ×
G for 10 minutes. The supernatant containing the diluted
plasma was discarded. The upper 40% of the cell pellet,
mainly consisting of white blood cells, was pipetted out.
This was mixed gently to make a homogenous cell suspen-
sion.
Plasma samples
Following identification of the infection by blood smear,
informed volunteers completed a single paroxysm with-
out drug treatment. The time of paroxysms was predeter-
mined by the increasing oral temperature (above 37.8°C)
and the presence of chills in most cases and supported by
examination of the blood smears made from these
patients. From the onset to the end of fever paroxysms
lasted 4 – 5 hours. Two milliliters of blood were collected
for plasma prior to the onset of paroxysm (pre-paroxysm
plasma samples) into 0.1% EDTA containing a protease
inhibitor (aprotinin; 0.6 trypsin inhibitor U/ml). A sec-
ond set of samples (paroxysm plasma) was collected at, or
within one hour of, the peak of a rigor and a third set, four
to six hours after the fever peak (post-paroxysm plasma).
Serum samples were collected from P.vivax-infected
patients, four to six weeks after drug cure (convalescent
serum).
Another set of plasma samples was collected from fever
patients admitted to the National Hospital of Sri Lanka
with oral temperatures above 37.8°C and blood film-neg-
ative for malarial parasites when tested at least twice on
consecutive days (non-malarial fever plasma).Malaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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Control plasma samples were collected from healthy vol-
unteers (normal human plasma).
Leukocyte aggregation
Whole blood cells were obtained from blood samples col-
lected from apparently healthy individuals. 80 μl of cell
suspension rich in white blood cells (obtained as
described under cell samples), was pipetted into 800 μl of
RPMI 1640 [1] in a 24-well tissue culture plate (Flow Lab-
oratories, UK) and 200 μl of test (paroxysm plasma, pre-
paroxysm plasma, post-paroxysm plasma, non-malarial
fever plasma or plasma from clinically semi-immune
endemic patients) or control plasma samples (normal
human plasma) were added into the cell suspension. The
culture plate was incubated for 3 hours at 37°C in an
incubator. The supernatant was discarded and from the
remaining cell pellet 40 μl was pipetted out and dispersed
evenly on a microscopic slide, in a circle of 1.5 cm diam-
eter using a template. These blood smears were air dried,
stained with Giemsa stain and examined under 400×
magnification.
Cell aggregation index
Blood smears were prepared from cultures containing
cells from healthy individuals incubated with test or con-
trol plasma samples as described above. Nucleated cell
aggregates containing five or more cells and the number
of un-clumped cells (that included single nucleated cells
and clumps of less than five cells) were counted in 100
microscopic fields and the total number of the nucleated
cells in these fields were also noted.
Based on these counts, a 'cell aggregation index' (CAI),
indicative of the ability of a particular plasma sample to
induce aggregation of white blood cells, was calculated as
follows:
CAI = ([Total no. of white blood cells/(No. of clumps +
no. of un-clumped white cells)] - 1), in 100 microscopic
fields at 400× magnification
% Relative Cell Aggregation Index (RCAI) = [CAI of test
sample/CAI of paroxysm plasma] × 100
Characterization of cell types involved in inducing cell 
aggregation
Monocytes
Monocyte depletion was done using two methods:
Method A
80 μl of cell suspension was diluted with 80 μl of a buffer
solution (containing Phosphate Buffered Solution/Foetal
Calf Serum at 1:1 ratio). This cell suspension was added
(at1:1 ratio) to a suspension of magnetic polystyrene
beads coated with a primary monoclonal antibody spe-
cific for the CD14 membrane antigen (Dynabeads M-450-
CD14, Dynal A.S., Oslo, Norway). This mixture was then
incubated for twenty minutes at 4°C. After incubation,
the tube containing the cell suspension was placed in the
magnetic particle concentrator (Dynal, MPC-1, Dynal A.S.
Oslo, Norway) which has a magnetic field to attract the
antibody coated Dynabeads together with the attached
cells. The remaining cells were pipetted out and this step
was repeated five times. The remaining cell suspension
(depleted of CD14 monocytes) was used for the relevant
experiments. Absence of monocytes from the cell suspen-
sion was confirmed using blood smears which were made
on glass slides, stained and examined under the micro-
scope.
Method B
80 μl of cell suspension was depleted of monocytes using
the plate-adherent method described previously [7].
Briefly, the white cell-rich cell suspension was incubated
at 37°C for 30 minutes in a polystyrene petri dish (size: 35
× 10 mm, Becton Dickinson and Co.) at 10% cell to liquid
volume in RPMI 1640. Then the supernatant containing
the non-adherent cells was carefully removed and the cells
were spun down.
Monocyte-depleted cells thus obtained by each method
were resuspended and used in the cell aggregation assay as
described above.
Monocyte reconstitution
For reconstitution experiments, a preparation of mononu-
clear cells was obtained from whole blood by sodium
metrizoate density gradient centrifugation (Lymphoprep,
Norway) according to standard procedure [1]. The mono-
nuclear cells were resuspended in RPMI 1640 pH 7.4 at
10% concentration and introduced into polystyrene petri
dishes (size: 35 × 10 mm, Becton Dickinson and Co.). 1
ml volumes at 2 × 107/ml concentrations were incubated
at 37°C for half an hour [7]. After incubation, the cell sus-
pension was pipetted out. The cells adhered on the surface
of the plate were scraped out with the rubber end of a 1 ml
syringe plunger and a cell count was taken using a haemo-
cytometer. Cells thus obtained (monocytes) were used for
reconstitution experiments at a concentration of 6 × 106
cells per well.
T cells
T cell depletion:T cells were depleted from 80 μl of cell
suspension by following the same procedures as adopted
in the case of macrophages, using Dynabeads coated with
antibodies specific for CD2 membrane antigen (Dyna-
beads-CD2, Dynal A.S., Oslo, Norway). The remaining (T
cell-depleted) cell suspension was used for relevant exper-
iments.Malaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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Identification of factors mediating cell aggregation
(i) Parasite factors
Effect of neutralization of parasite factors on paroxysm plasma-
induced cell aggregation
Serum containing anti-parasite antibodies i.e. hyper-
immune rabbit serum raised against freeze-thawed
extracts of either P. vivax or  P. falciparum [2] or with
human convalescent serum was pre-incubated with par-
oxysm plasma at 1:1 of concentration for 30 minutes
before incubating with un-primed whole blood cells col-
lected from healthy individuals.
Effect of re-constitution of parasite factors in normal human plasma 
treated with freeze-thawed P. vivax schizont extracts
Normal human plasma obtained from healthy individu-
als were reconstituted with freeze-thawed extracts of 5 ×
106 P. vivax schizonts per ml or 5 × 106 of uninfected red
blood cells per ml as a control prepared as previously
described [1]. This re-constituted plasma was incubated
with unprimed whole blood cells of healthy individuals.
As a control, normal human plasma was reconstituted
with E. coli lipopolysaccharide (LPS) at a final concentra-
tion of 2 μg/ml and tested in cell aggregation assay as pre-
viously described [1].
(ii) Host factors
Cytokines
Involvement of cytokines in the mediation of cell aggrega-
tion by paroxysm plasma was investigated by their neu-
tralisation with anti-cytokine antibodies and
reconstitution with the addition of recombinant human
cytokines. The optimum concentrations of anti-cytokine
antibodies and recombinant cytokines required to over-
come the neutralization imposed by the antibodies were
determined based on experiments using dilution series of
these, using the same principles and methodologies
adopted in previous studies [8].
Depletion and reconstitution of plasmas with specific components
Depletion experiments
Paroxysm plasmas were pre-incubated at 37°C for 30
minutes with the following immune reagents, singly or in
combination, before assessing the effect on paroxysm
plasma-induced cell aggregation.
(i) Rabbit polyclonal antibodies (IgG) against human IL1-
α [0.014 μg/ml], IL1-β [0.075 μg/ml], IL-2 [1.5 μg/ml], IL-
3 [5 μg/ml], IL-4 [0.125 μg/ml], IL-6 [0.1 μg/ml], IL-10
[7.5 μg/ml], IFNγ [5 μg/ml], TNF-α [0.04 μg/ml], TNF-α
[0.05 μg/ml] and GM-CSF [5 μg/ml] (R&D systems, UK).
Reconstitution experiments
Recombinant human cytokines (IL1-α [5 pg/ml ], IL1-β
[7.5 pg/ml], IL-2 [0.375 ng/ml], IL-3 [0.25 ng/ml], IL-4
[0.125 ng/ml], IL-6 [0.5 ng/ml], IL-10 [0.75 ng/ml]), IFNγ
[1.15 ng/ml ], TNF-α [0.05 ng/ml], TNF-α [0.03 ng/ml]
and GM-CSF [0.05 ng/ml] were added to cytokine-
depleted paroxysm plasma to confirm the involvement of
cytokines in paroxysm plasma-induced cell aggregation.
Recombinant human cytokines were also added to nor-
mal human plasma or post paroxysm plasma in other
experiments. Freeze-thawed extracts of 5 × 106/ml P. vivax
schizonts or 5 × 106/ml of uninfected red blood cells as a
control (prepared as previously described, [1]) were
added to plasmas in relevant experiments.
The physical/chemical characterization of plasma factors
of putative parasite origin that mediate leukocyte aggrega-
tion.
Heating
Paroxysm plasma and normal human plasma, as a con-
trol, were heated in 1 ml volumes in a water bath at 60°C,
80°C or 100°C for five minutes before testing in the cell
aggregation assay. The heat-treated fraction of paroxysm
plasma, was reconstituted either with an extract of P. vivax
schizonts or with recombinant human cytokines (rh TNF-
α, rh GM-CSF, rh IL-10, rh IL-6) and tested for cell aggre-
gation.
Ultra-centrifugation
Paroxysm plasma and normal human plasma were centri-
fuged in 1 ml volumes at 180,000 × G for 15 minutes at
4°C. Two layers were formed. The thin opaque, whitish
upper layer was removed in 100 to 200 ul. The remaining
liquid was yellowish but clear and was retained as a single
fraction. The two fractions were tested separately and
reconstituted with recombinant human cytokines (rh
TNF-α, GM-CSF, IL-10, IL-6) or with P. vivax schizont
extract and re-tested in the cell aggregation assay. The sep-
arated fractions were also tested for lipids (standard
Sudan III test) [9].
Filtration
1 ml samples of paroxysm plasma or normal human
plasma were passed through 0.45 μm millipore filters
(Flow laboratories, UK) and the filtrates were tested in the
cell aggregation assay. The filtrates were re-tested in the
cell aggregation assay following reconstitution with
recombinant human cytokines (rh TNF-α, GM-CSF, IL-6,
IL-10) or P. vivax schizont extracts.
Extraction and fractionation of lipids
1 ml samples of paroxysm plasma, or 1 ml of normal
human plasma (NHP) as a control, were heated at 100°C
for five minutes in a water bath. Freeze-thawed extracts of
P. vivax schizonts at 5 × 106 schizonts in 1 ml of NHP were
also heat-treated in the same way. The following extrac-
tions were then carried out, all at room temperature, usingMalaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
Page 5 of 14
(page number not for citation purposes)
standard biochemical techniques [10-12]. Briefly, each of
the heat-treated plasma samples was extracted first with 1
ml of acetone, centrifuged for 10 seconds at × 15,000 × G
and the supernatant retained as fraction 1 (cholesterol,
triglycerides); the pellet was extracted with 1 ml of 95%
ethanol, spun as before and the supernatant retained as
fraction 2 (lecithin); the pellet was extracted in 1 ml of
petroleum-ether, spun as before and the supernatant
retained as fraction 3 (composition unidentified). The
pellet obtained, and half of the retained fraction 3, were
added together and extracted with 1 ml of diethyl-ether,
spun as before, and the supernatant retained as fraction 4
(phospholipids) and the pellet as fraction 5 (sphingolip-
ids). Each of these fractions was evaporated to dryness by
flushing with nitrogen gas. The residues were dissolved in
1 ml either of normal human plasma or of normal human
plasma reconstituted with recombinant human cytokines
(rh TNF-α, GM-CSF, IL-6 & IL-10) as described above and
then tested in the cell aggregation assay.
Statistical analysis
As the data dispersion was found to be not normal, Mann-
Whitney U test was applied to compare two groups and
Kruskal – Wallis test was applied when there were more
than two groups to be compared and the post hoc signifi-
cance was analysed. Median values were given with inter-
quartiles (as 25%–75% percentiles). (statistical software
package – SPSS 10.0 for Windows).
Ethical clearance
All aspects of the study were approved by the Ethical
review committee of Faculty of Medicine, University of
Colombo, Sri Lanka. Informed-written consent was
obtained from all participants.
Results
Aggregation of white blood cells from healthy donors in the 
presence of paroxysm plasma from acute P. vivax-infected 
patients
Striking changes in the distribution of nucleated cells were
observed between smears made from cultures in which
whole peripheral blood cells from healthy individuals
were incubated in the presence of paroxysm plasma from
acute P. vivax-infected patients when compared with cul-
tures incubated in the presence of normal human plasma.
In smears made from cultures with normal plasma
(NHP), most of the nucleated white blood cells were dis-
tributed in the smear either as single cells or in small
aggregates of not more than 2–3 cells per cluster. In con-
trast, in blood smears of cultures containing paroxysm
plasma (PP), obvious, large aggregations of nucleated
white blood cells were seen, with a significantly high cell
aggregation index (CAI) [Figure 1: (p < 0.001 when com-
pared with NHP)].
The aggregates were composed predominantly of neu-
trophils (80% – 90%), monocytes and lymphocytes. They
varied in size, ranging from five to100 cells with an aver-
age of 20. Marked aggregations of white blood cells with
high cell aggregation indices were observed in the pres-
ence of all paroxysm plasma collected from non-immune
patients who presented with acute P. vivax infections (Fig-
ure 1; PP).
There were very few cell aggregates seen in smears made
from cultures containing pre-paroxysm plasma with
resultant low cell aggregation indices (Figure 1; PRP); p <
0.001 relative to paroxysm plasma) or post-paroxysm
plasma (Figure 1; POPP) (p < 0.001 relative to paroxysm
plasma). These results demonstrate a tight coincidence in
timing between the period of prominent clinical symp-
toms during paroxysms in P. vivax infections and the pres-
ence of plasma mediators that induce the aggregation of
white blood cells in vitro.
The robustness (repeatability) of this bioassay system was
tested by calculating the co-efficient of variation of the
CAI for different PP samples (n = 21) and the same PP
samples in repeated experiments (n = 6). The co-efficient
of variation of the CAI ranged between 0 and 10% (except
3 values which were between 15% and 50%).
The absence of the leukocyte aggregation-inducing factors 
in paroxysm plasma from semi-immune P. vivax patients 
and evidence for serum-mediated immunity against 
parasite factors/"toxins"
In contrast to the induction of leukocyte aggregation by
paroxysm plasma from the clinically non-immune
patients from Colombo, plasmas collected during parox-
ysm from age-matched, semi-immune, acutely infected P.
vivax patients resident in Kataragama, an endemic area of
Sri Lanka, had little such effect (Figure 1; EPP) (p < 0.001
relative to paroxysm plasmas from non-immune
patients). These findings indicated an association
between the absence of the cell aggregation-mediating
activity in infection plasma and tolerance to the symp-
toms of paroxysms during malarial infection.
Convalescent serum collected following recovery from a
P. vivax infection from these semi-immune endemic resi-
dents when pre-incubated with PP reduced the aggrega-
tion index of non-immune paroxysm plasma by 83%
(Table 1: Expt.15 cf Expt.2; p < 0.05). Together with evi-
dence that parasite products released during schizogony
are active mediators of cell aggregation in vitro (see
below), this finding suggests that clinical immunity may
be associated with the presence of antibodies against these
active parasite products.Malaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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The absence of the leukocyte aggregation inducing factors 
in plasmas of non-malarial fever patients
Plasma samples which were obtained from febrile
patients attending the National Hospital of Sri Lanka in
Colombo, who were blood film-negative for malarial par-
asites (NMFP) did not cause any significant aggregation of
white blood cells when compared with paroxysm plasma
(Figure 1; NMFP; p < 0.001 relative to paroxysm plasma)
indicating that the active factors present in paroxysm
plasma were specific to malarial infections, though it
remains a possibility that synchronised schizongony that
operates prior to a paroxysm could trigger agent(s) that
Cell aggregation-inducing effect of plasma samples Figure 1
Cell aggregation-inducing effect of plasma samples. Blood samples were collected for plasma before, during and after 
paroxysm from non-immune Plasmodium vivax-infected patients, healthy individuals, non-malarial fever patients and from 
malaria patients resident in an endemic area (malaria semi-immune individuals); plasmas from these blood samples were tested 
for their ability to induce white blood cell aggregation in vitro. (p < 0.001: Kruskal Wallis test; p values of post hoc significance 
(Mann Whitney U test) are indicated in the text). NHP: Normal Human Plasma; PRP: Pre Paroxysm plasma; PP: Paroxysm 
Plasma; POPP: Post Paroxysm Plasma; NMFP: Non Malarial Fever Plasma; EPP: Endemic Paroxysm Plasma
0.0000
0.5000
1.0000
1.5000
2.0000
2.5000
(          ) : median 
NHP  PRP PP POPP NMFP EPP
C
e
l
l
 
A
g
g
r
e
g
a
t
i
o
n
 
I
n
d
e
x
 
(
C
A
I
)
Table 1: Effect of plasma samples, cytokines and parasite products in the white blood cell aggregation assay
Expt. No. Sample % RCAI (Median) 25% 75%
1N H P 5 . 8 0 1 . 6 7 . 3
2 PP 100 100.0 100.0
3 POPP 20.90 5.6 28.4
4 NHP+cytokines 17.20 6.7 23.5
5 NHP+PvAg 18.60 4.5 20.8
6 NHP+PvAg+ cytokines 88.50 79.8 92.4
7 NHP+RBC Ag+ cytokines 10.00 2.4 12.9
8 POPP+cytokines 18.30 7.5 22.3
9 POPP+PvAg 16.40 9.4 18.1
10 POPP+PvAg+ cytokines 77.10 64.7 79.8
11 NHP+LPS 6.10 1.9 7.2
12 NHP+LPS+cytokines 16.10 6.9 18.6
13 PP + IRS-Pv 24.90 15.6 28.4
14 PP + IRS-Pf 54.40 48.6 65.4
15 PP + CHS 17.00 14.2 19.5
% RCAI: % Relative Cell Aggregation Index
25%–75%: 25th and 75th percentiles
Normal human plasmas (NHP) and post paroxysm plasmas (POPP) were reconstituted with freeze-thawed extracts of P. vivax schizonts (Pv Ag), 
normal red cell extracts (RBC Ag), recombinant human cytokines TNF-∝, GM-CSF, IL-6 and IL-10 (cytokines) or E. coli lipopolysaccharide (LPS). P. 
vivax paroxysm plasma (PP) was pre-incubated with rabbit serum raised against P. vivax schizonts (IRS-Pv), with rabbit serum raised against P. 
falciparum schizonts (IRS-Pf) or with convalescent human serum (CHS) collected 4 – 6 weeks after drug cure of a P. vivax infection, from semi-
immune individuals resident in a malaria-endemic area prior to being tested in the cell aggregation assay. The table provides the median values 
together with the interquartile range (25%–75%).Malaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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might be more concentrated in malarial plasma as
opposed to in plasma from other febrile infections.
The effects of the removal of monocytes or T lymphocytes 
on the aggregation of white blood cells mediated by 
paroxysm plasma from acute P. vivax-infected patients
The degree of leukocyte aggregation mediated by parox-
ysm plasma from acute P. vivax-infected patients was
markedly reduced when monocytes were depleted from
the leukocyte suspension prior to incubation with parox-
ysm plasma (p < 0.05 relative to that with undepleted
white blood cells) and was restored to some extent by
reconstitution of the cell suspension with monocytes (p >
0.05 relative to that with undepleted white blood cells –
Figure 2). No similar reduction in white cell aggregation
was seen when T lymphocytes were depleted from the cell
suspension (p > 0.05 relative to undepleted white blood
cells). The findings indicate a likely role of monocytes in
the formation of cell aggregates.
Cytokines and probable parasite products are the active 
mediators of the paroxysm plasma-induced leukocyte 
aggregation phenomenon
Pre-incubation of PP with anti-cytokine antibodies viz. IL-
1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-10, IFN γ, TNF-α and
GM-CSF, reduced the PP-induced leukocyte aggregation
by 45% – 76% (Figure. 3). However, reconstitution of the
cytokine-depleted plasmas with the recombinant human
cytokines caused over 50% recovery of paroxysm plasma-
induced cell aggregation only in the case of TNF-α, GM-
CSF, IL-6 or IL-10 (Figure 3) suggesting that these are the
principal cytokines involved in inducing leukocyte aggre-
gation. However, TNF-α, GM-CSF, IL-6 and IL-10 induced
little leukocyte aggregation, either when added to normal
human plasma singly (data not shown) or in combina-
tion (Table 1: Expt.4 cf Expt.1) or when they were added
to post-paroxysm plasma (Table 1: Expt.8 cf Expt.3).
These findings suggested that, in addition to these
cytokines, further active factor(s), which are absent from
both normal human plasma and post paroxysm plasma,
must be present in paroxysm plasma to induce leukocyte
aggregation. It was postulated that these additional factors
could be parasitic in origin. To test this hypothesis, parox-
ysm plasmas were pre-incubated with immune serum
which had been raised in rabbits against P. vivax blood
stage schizonts. This treatment greatly reduced (by 75%)
the paroxysm plasma-induced cell aggregation (Table 1:
Expt.13 cf Expt.2; p < 0.05). Similarly, cell aggregate-
inducing activity of paroxysm plasma was reduced when
pre-incubated with convalescent sera collected following
P. vivax infections in semi-immune individuals (Table 1:
Expt.15; p < 0.05). These results suggest a likely role of
parasite-derived molecules in this phenomenon.
Paroxysm plasma-induced cell aggregation was also
inhibited, although to a lesser extent (by 46% only), by
immune rabbit sera raised against P. falciparum blood
stage schizonts (Table 1: Expt.14 cf Expt.2; p < 0.05). This
suggests that the active molecules of putative parasite ori-
gin have species cross-reactive components. However, in
view of the lesser effect of the anti-P. falciparum immune
serum compared to that of antiserum raised against P.
vivax schizont extracts (p < 0.05), species-specific active
moieties could also be involved.
Induction of leukocyte aggregation in vitro with extracts 
of P. vivax blood stage schizonts
The hypothesis that moieties of parasite origin might be
involved in mediating the in vitro aggregation of white
cells was further investigated. It was found that a strong
leukocyte aggregation could, indeed, be induced by the
addition of the combination of freeze-thawed extracts of
P. vivax schizonts (but not extracts of uninfected human
RBCs) and the cytokines rhu-TNF-α, GM-CSF, IL-6 and IL-
10 to normal human plasma (Table 1: Expt.6 cf, Expts.7 &
1;) or to post paroxysm plasma (Table 1: Expt.10 cf
Expt.3). By contrast, neither the cytokines nor the P. vivax
schizont extract had any significant level of activity when
added either to normal human plasmas on their own
(Table 1: Expts. 4 & 5) or to post paroxysm plasma (Table
1: Expts.8 & 9). Moreover, the bacterial endotoxin,
lipopolysaccharide (LPS), failed to substitute for the P.
vivax schizont extracts in mediating these effects (Table 1:
Expts.11 & 12).
These results are consistent with the hypothesis that the
active, non-cytokine, factors in paroxysm plasma from
non-immune patients who presented with acute P. vivax
infections, which are involved in mediating white cell
aggregation in vitro, are products of the parasites them-
selves and are specific to Plasmodium if not to P. vivax itself
(see previous section of results). They cannot, for example
be substituted for by a bacterial endotoxin such as LPS.
Effect of heating, filtration and ultra-centrifugation of 
paroxysm plasma from acute P. vivax – infected patients 
on the induction of leukocyte aggregation
Heating
Paroxysm plasma heated in a water bath at, or above,
80°C almost completely lost its ability subsequently to
induce leukocyte aggregation. Thus, the CAI of paroxysm
plasma heated at 100°C (hPP-100°C) was significantly
lower than that of untreated paroxysm plasma (p < 0.05).
The effect was completely restored, however, by addition
of the "effective" cytokine combination (rhu-TNFα, GM-
CSF, IL-6 and IL-10, as identified in this study) to heat-
inactivated paroxysm plasma (bPP + Cyto) with CAI of
bPP + Cyto being significantly higher when compared to
that of heat-inactivated paroxysm plasma on its ownMalaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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(hPP-100°C); p < 0.05. By contrast, addition of P. vivax
schizont extracts to the heat-inactivated paroxysm plasma
(bPP + ScE) had little capacity to restore the white cell
aggregating activity (p > 0.05) (Figure 4).
These results demonstrate that there is a heat stable (with-
standing temperature up to 100°C) activity in paroxysm
plasma obtained from acute P. vivax-infected patients,
which is dependent upon the presence of the heat labile
"effective" cytokine combination to mediate leukocyte
aggregation. The material mediating the heat stable activ-
ity is likely to be of parasite origin.
Filtration
Filtration of paroxysm plasma (0.45 μm filters, Milipore-
Sartorius AG), reduced, but did not eliminate, its ability to
induce white cell aggregation (Figure 4) indicating that
some of the active components in paroxysm plasma are in
particulate form. Addition of the "effective" cytokines to
the filtered plasmas did not restore the activity while addi-
tion of a P. vivax schizont extract did (Figure 4). This sug-
gests that the activity reduced by filtration is likely to be
parasite in origin.
Centrifugation
High-speed centrifugation of paroxysm plasma, or of nor-
mal human plasma as a control, produced two layers. The
upper layer was thin and opaque but was wider and more
distinct in paroxysm plasma compared to normal human
plasma; this layer tested strongly positive for lipids in the
Sudan III test. The lower layer was a clear solution both in
paroxysm plasma and in normal human plasma and was
negative for lipids by the Sudan III test. Compared to the
original paroxysm plasmas from which they were derived,
the material in each layer had greatly reduced ability to
induce white cell aggregation (Figure 4). However, the
activity was largely restored to the material in the top layer
by the addition of cytokines (but not of P. vivax schizont
Role of monocytes and lymphocytes in cell aggregation induced by Plasmodium vivax paroxysm plasma Figure 2
Role of monocytes and lymphocytes in cell aggregation induced by Plasmodium vivax paroxysm plasma. White 
blood cell suspensions were depleted of monocytes or lymphocytes prior to incubation with paroxysm plasma samples (n = 6) 
in the cell aggregation with or without reconstitution with these cell types. The bars indicate the median values of the data 
series together with the interquartile range (25%–75%). PP: paroxysm plasma; NHP: normal human plasma; WBC: white blood 
cells; T*: T cells depleted by Dynabeads (anti CD2), M *: monocytes depleted by Dynabeads (anti CD14), M**: monocytes 
depleted by panning method; M: monocytes recovered from panning method.
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extracts); activity was restored to the material in the bot-
tom layer by the addition of P. vivax schizont extracts (but
not cytokines) (Figure 4).
These results indicate that the active factors of putative
parasite origin in paroxysm plasmas from non-immune
patients infected with P. vivax infections were concen-
trated in the top, lipid-rich, layer and the cytokines were
in the bottom, lipid-free, layer of the plasmas following
high-speed centrifugation.
The white blood cell-aggregating activity of different lipid-
containing fractions of paroxysm plasma and P. vivax 
schizont extracts
Except for one fraction (P1); (Table 2; Exp 1), the other
four lipid fractions extracted from heat-treated paroxysm
plasma (P2 to P5) and freeze-thawed extracts of P. vivax
schizonts (S1 to S5) showed very little effect when tested
on their own in the cell aggregation assay (Table 2: Expts.
2–5 and 11–15 respectively). However, when reconsti-
tuted with the recombinant human cytokines rh TNF α, rh
GM-CSF, rh IL-10 and rh IL-6, two of the five lipid frac-
tions, one containing cholesterol/triglycerides (P1 and
S1) and the other which contains phospholipids (P4 and
S4) induced significant levels of cell aggregation (Table 2:
Expts. 6 & 16 and 9 & 19 respectively).
In the lipid fractions of the P. vivax schizont extract, the
more prominent effect was seen in the phospholipid-con-
taining fraction (S4) (Table 2: Expt. 19). By contrast, the
greatest activity from the paroxysm plasma was in the cho-
lesterol/triglyceride fraction (P1) (Table 2: Expt.6). More-
over, the cell aggregating activity in this fraction was quite
high even without addition of cytokines, which added rel-
atively little to its activity (Table 2: Expts 1 & 6). This sug-
gests that the lipids in this fraction may be competent to
The effect of cytokines in white blood cell aggregation mediated by Plasmodium vivax paroxysm plasma Figure 3
The effect of cytokines in white blood cell aggregation mediated by Plasmodium vivax paroxysm plasma. Plasmas 
obtained from non-immune Plasmodium vivax – infected patients (n = 6) during a paroxysm (PP) were tested in the cell aggrega-
tion assay following depletion and then reconstitution of that cytokine. The untreated paroxysm plasmas (PP) and normal 
human plasmas (NHP) were used as positive and negative controls. The bars indicate the median values of the data series 
together with the interquartile range (25%–75%).
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induce the necessary cytokines themselves, whereas those
in other fractions of paroxysm plasma, and those from the
schizont extract, are not. The results indicate that the
active parasite-derived materials in the paroxysm plasmas
and in those in the schizont extracts differ from each other
either quantitatively or qualitatively.
Discussion
The present study describes an in vitro phenomenon, the
aggregation of white blood cells, which is mediated by the
activity of factors present in plasma taken at the time of a
paroxysm of P. vivax malaria. In the presence of paroxysm
plasma from non-immune P. vivax-infected patients,
aggregates were formed by white blood cells collected
from healthy uninfected and malariologically-naive indi-
viduals. Similar aggregates were also seen when cells were
obtained from P. vivax-infected patients and similarly
incubated with paroxysm plasma. Although the biological
relevance of such aggregate formation remains specula-
tive, it might be a scavenging mechanism used by the host
to get rid of the parasite debris released following schizont
rupture [13].
Leukocyte activation associated with fever episodes has
been shown in P. vivax malaria [14]. Peripheral leukope-
nia in P. vivax infections has been observed to be at its
maximum during paroxysms (authors' unpublished
observations). Pulmonary accumulation and sequestra-
tion of neutrophils and monocytes have been seen in
murine models [15,16]. Furthermore, pulmonary oedema
has been reported in P. vivax malaria [17], which may be
due to accumulation of leukocytes. In P. falciparum
malaria, cyto-adherent infected erythrocytes that bind to
leukocytes enhance antibody-independent phagocytosis
and induce cellular aggregation [18]. Pancytopaenia,
especially thrombocytopaenia is common in malaria
patients [19,20]. These findings provide indirect evidence
as to the possible in vivo significance of such aggregate for-
mation in malarial infections.
Characterization of biologically active factor(s) in Plasmodium vivax paroxysm plasma Figure 4
Characterization of biologically active factor(s) in Plasmodium vivax paroxysm plasma. Paroxysm plasmas from P. 
vivax patients (n = 6) were tested in the white blood cell aggregation assay before and after treatment of the plasmas by heat-
ing, filtration or centrifugation and with or without supplementation with recombinant human cytokines or freeze-thawed par-
asite schizont extracts. The bars indicate the median values of the data series together with the interquartile range (25%–75%). 
PP: Paroxysm plasma (untreated); NHP: normal human plasma (untreated); hPP: paroxysm plasma pre-heated at the indicated 
temperature; bPP: paroxysm plasma pre-treated at 100°C; PP-A: top layer of centrifuged paroxysm plasma; PP-B: bottom layer 
of centrifuged paroxysm plasma; Cyto: cytokines (TNF-∝, GM-CSF, IL-6 and IL-10); ScE: freeze-thawed P. vivax schizont 
extract.
0
20
40
60
80
100
120
140
%
 
R
e
l
a
t
i
v
e
 
C
e
l
l
 
A
g
g
r
e
g
a
t
i
o
n
 
I
n
d
e
x
 
(
R
C
A
I
)
P
P
N
H
P
h
P
P
-
6
0
0
C
h
P
P
-
1
0
0
0
C
h
P
P
-
8
0
0
C
b
P
P
+
C
y
t
o
b
P
P
+
S
c
E
F
i
l
t
r
a
t
e
F
i
l
t
r
a
t
e
 
+
C
y
t
o
f
i
l
t
r
a
t
e
 
+
S
c
E
P
P
-
A
P
P
-
B
P
P
-
A
+
C
y
t
o
P
P
-
B
+
C
y
t
o
P
P
-
A
+
S
c
E
P
P
-
B
+
S
c
EMalaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
Page 11 of 14
(page number not for citation purposes)
The active plasma factors, which mediated the cell aggre-
gation included heat-labile substances consisting of
mainly the monocyte-derived cytokines TNFα, GM-CSF
and IL-6 and a T cell-derived cytokine IL-10. However, the
activity of these cytokines in mediating leukocyte aggrega-
tion was absolutely dependent upon the simultaneous
presence of heat-stable, and presumably parasite-derived,
material released into the plasma at the time of a P. vivax
paroxysm. It has been reported that aggregation of neu-
trophils may develop in EDTA – anti-coagulated blood
[21]. However, in the present study EDTA-dependent
aggregation of white blood cells can be excluded based on
the experiments carried out using normal human plasma
samples obtained from healthy individuals into similar
EDTA concentrations, which did not show aggregation.
Moreover, immune serum raised against P. vivax parasites
could reverse this effect.
Ever since the description, at the end of the 19th century,
of the synchronous rupture of blood stage schizonts dur-
ing human malarial infections and the association of
these events with the periodic fevers of malaria, it has
been clear that parasite products released into the plasma
by the rupturing schizonts must be crucial to the initiation
of a malarial paroxysm [22]. Evidence for the existence of
malaria paroxysm-associated pyrogens, or "malaria tox-
ins" as they were known, was provided by demonstrating
that plasma from an individual undergoing a paroxysm of
P. vivax malaria could rapidly induce equivalent symp-
toms when the plasma was injected into the circulation of
a healthy volunteer [23]. Thus the concept of a malaria
toxin is not novel [2,13,22-26]. It is now evident that the
mediators of a malarial paroxysm, which include the par-
asite products, or "toxins", themselves, are involved in
interactions with and between circulating white blood
cells.
In addition to cytokines, the activated white blood cells
release free radicals and other active molecular intermedi-
ates [27,28]. These mediators of inflammatory and patho-
genic effects and also anti-parasitic effects [29-33] are
speculated to help control parasite densities at the initial
phase of a malarial infection. Inhibition of the maturation
of P. falciparum schizonts in vitro by paroxysm serum from
a case of P. vivax malaria has been demonstrated by other
workers [33]. Similar anti-parasitic effect of paroxysm
plasma from acute P. vivax-infected patients has been
demonstrated to induce suppression of infectivity of
Table 2: Leukocyte aggregation-inducing effects of lipid fractions of Plasmodium vivax paroxysm plasma and of P. vivax schizont 
extracts with or without supplementation with recombinant human cytokines (TNFα, GM-CSF, IL-6 and IL-10).
Expt. No. Sample % R CAI (Median) 25% 75%
1 P1 26.30 20.10 30.60
2 P2 4.50 3.40 8.60
3 P3 4.20 3.50 6.40
4 P4 8.50 6.80 11.80
5 P5 1.00 0.20 1.30
6 P1 + Cytokines 38.20 34.20 46.50
7 P2 + Cytokines 8.70 5.60 10.90
8 P3 + Cytokines 8.60 4.60 12.40
9 P4 + Cytokines 24.60 22.50 31.70
10 P5 + Cytokines 1.20 0.50 3.60
11 S1 3.1 1.4 6.4
12 S2 2.5 1.3 5.9
13 S3 2.9 1.2 7.4
14 S4 14.3 12.3 18.6
15 S5 1 0.2 2.4
16 S1 + Cytokines 10.4 7.6 13.9
17 S2 + Cytokines 3.8 2.5 6.4
18 S3 + Cytokines 2.7 1.9 6.5
19 S4 + Cytokines 26.2 21.9 30.4
20 S5 + Cytokines 1.1 0.3 2.1
% RCAI: % Relative Cell Aggregation Index (median)
25%–75%: 25th and 75th percentiles
Different fractions of P. vivax schizont extracts (S1 – acetone fraction, S2 – ethanol fraction, S3 – petroleum ether fraction, S4 – diethyl ether 
fraction and S5 – remaining fraction ) and similar fractions of paroxysm plasma ( P1 – acetone fraction, P2 – ethanol fraction, P3 – petroleum ether 
fraction, P4 – diethyl ether fraction and P5 – remaining fraction ) were tested for their ability to induce cell aggregation with or without 
supplementation with recombinant human cytokines (TNFα, GM-CSF, IL-6 and IL-10).
The table provides the median values together with the interquartile range (25%–75%).Malaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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malarial gametocytes to mosquitoes [1]. Like the cell
aggregation effect described here, paroxysm-associated
inactivation of gametocytes is mediated by cytokines and
parasite products released at the time of the paroxysm
[1,2,13]. In both the cell aggregation and the gametocyte
inactivation phenomena, however, the parasite materials
and moieties involved remain to be identified.
This paper describes the initial attempts made at charac-
terization of the nature of these active parasite products. It
is shown here that the heat-stable, cell-aggregating activity
present in the paroxysm plasmas has the following prop-
erties. It is present in, and only in, plasmas taken at the
time of the acute symptoms of a P. vivax paroxysm. No
equivalent activity is present either before the acute symp-
toms begin or more than one or two hours after they
cease. No equivalent activity is found in association with
non-malarious fevers. The white cell-aggregating activity
can be effectively substituted by extracts of schizonts of
either P. vivax or P. falciparum when these are added to
normal human plasmas in the presence of the cytokine
combination identified above. Moreover, the activity in
the paroxysm plasmas from acute P. vivax-infected
patients is neutralised in the presence of immune sera
raised against extracts of schizonts of either P. vivax or P.
falciparum. The activity is more effectively neutralised by
immune serum against P. vivax than that against P. falci-
parum, and is supportive evidence of parasite species-spe-
cificity.
These properties of the putative parasite-derived activity
in P. vivax paroxysm plasma in relation to white cell aggre-
gation are indistinguishable from those identified in rela-
tion to paroxysm plasma-mediated gametocyte
inactivation [1,2,13,34]. The difference between the
mediators involved in these two paroxysm-associated
phenomena lies in the combination of cytokines
involved. Thus the necessary and sufficient cytokines
involved in gametocyte inactivation are the monocyte-
derived cytokines TNFα, GM-CSF and the T cell derived IL-
2; those involved in the white cell aggregation are princi-
pally the monocyte-derived TNFα, GM-CSF and IL-6 and
the mainly T cell derived cytokine IL-10. In both phenom-
ena the immediate presence of monocytes was shown to
be essential. On the other hand, the depletion of T lym-
phocytes did not affect cell aggregation. This does not,
however, exclude a role for T cells at an earlier stage in the
events of a paroxysm as, for example, during the induc-
tion of other cytokines involved in the process. This is
probably because, the T cell-derived cytokines having
already been induced by the time of the active paroxysm.
Therefore, the continued immediate presence of the T
cells is no longer essential for either gametocyte inactiva-
tion or white cell aggregation to take place. Though, T cells
strongly respond to phosphoantigens from Plasmodium
parasites [35], prolonged exposure to P. vivax malaria
infections in endemic areas are known to cause immuno-
suppression of human T cells [36].
The cell aggregation phenomenon was used as an assay to
explore the physical and chemical nature of the heat sta-
ble, and presumably parasite-derived, activity in the par-
oxysm plasmas from acute P. vivax-infected patients.
Results indicate a prominent role of cholesterol and trig-
lycerides containing fraction of paroxysm plasma in medi-
ating cell aggregation even in the absence of added
cytokines. Only one other fraction gave significant activ-
ity. This was the phospholipid fraction and this activity
was largely dependent upon the presence of the added
cytokines. Equivalent lipidic fractions were made from
extracts of schizonts of P. vivax but significant, and largely
cytokine-dependent, activity was found only in the phos-
pholipid fraction. Interestingly the characteristics of this
fraction were congruent with those of the malaria para-
site-derived TNF-inducing GPI moieties studied by other
workers [37-43]. GPI surface-anchored antigens including
MSP-1 have been viewed as potential candidates for vac-
cine development [44,45]. Studies in other laboratories
have demonstrated lipogenesis-inducing activity in the
lipid fractions of boiled supernatant of P. falciparum cul-
tures [46] with subsets of T lymphocytes being affected at
an early stage during paroxysms of non-endemic malaria
infections [35].
Conclusion
This study identifies leukocyte aggregation as a phenome-
non associated with paroxysms in P. vivax infections. This
phenomenon is mediated by plasma factors including
host-derived cytokines and lipids of putative parasite ori-
gin. Most of the parasite-derived activity lies in the choles-
terol/triglyceride and phospholipid fractions of paroxysm
plasma and especially in the former fraction. Activity in
this cholesterol/triglyceride-containing fraction is poorly
represented in extracts of P. vivax schizonts prepared in
vitro. Therefore, only P. vivax paroxysm plasma itself, and
not artificial extracts of parasite material prepared in vitro,
represent an adequate source of the biologically active
parasite-derived mediators present during such a parox-
ysm. The characteristics of the phospholipid fraction in
paroxysm plasma are congruent with those of the malaria
parasite-derived, TNF-inducing GPI moieties described by
other workers. The more active cholesterol/triglyceride(s),
on the other hand, represent a new class of biologically
active lipid associated with the paroxysm of P. vivax
malaria.
In future investigations, it is planned to explore further
the chemical characterisation of active parasite-derived
mediators associated with the paroxysm of P. vivaxMalaria Journal 2007, 6:62 http://www.malariajournal.com/content/6/1/62
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malaria using P. vivax paroxysm plasma itself as the source
of the active moieties.
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